Vaxine Pty Ltd is a rapidly growing Australian biotechnology company based in Adelaide that has developed an impressive pipeline of vaccines against infectious disease, allergy, and cancer. Vaxine has developed the Advax range of proprietary polysaccharide adjuvants and is currently applying this state of the art adjuvant technology to the development of vaccines against hepatitis B, pandemic influenza, Japanese encephalitis, West Nile virus, malaria, HIV and rabies, amongst others.